CHD1 and prostate carcinoma: While tumour TL was not associated with any known prostate cancer-related genomic rearrangement (GR) or single-nucleotide variant (SNV) at current statistical power, samples with CHD1, RB1 or NKX3-1 deletions had shorter tumour TL (Fig. 1d).